Commonwealth Biotechnologies, Inc. Receives Notice of Allowance From US Patent and Trade Office
Guess this confirms CBTE is in the genomics field
RICHMOND, Va., Feb. 17 /PRNewswire/ -- Commonwealth Biotechnologies, Inc., (Nasdaq: CBTE - news), a biotechnology contract research organization,
announced today that it has received a Notice of Allowance and Notice of Allowability from the US Patent and Trademark Office for its automated DNA
sequencing reagent, AccuTrac(TM), and the process for which it is used. AccuTrac(TM), which is used to unequivocally identify individual lanes in a DNA gel, will
be especially valuable in sequencing of genomes and other large sequencing projects. The product will minimize the need to manually confirm locations of samples in a
gel and will thereby increase the accuracy of the sequencing data generated.
''AccuTrac(TM) will have a definite impact on sequencing accuracy and quality assurance, not only for CBI's own genome projects, but also for those of other
genome companies and the large genome centers doing high throughput DNA sequencing,'' said Thomas R. Reynolds, Senior Vice President of CBI and one of the
inventors of the product. ''A very significant advantage of this product is that it can be used with nearly all automated DNA sequencers without any hardware or
software modifications,'' Reynolds added.
The company has carried out beta testing and limited marketing of the product since its introduction at The Institute for Genomic Research (TIGR) Microbial
Genomics meeting in January of 1999. ''User feedback has been very positive, and with the intellectual property protection in place, we will move aggressively to
license this technology to partners in the global biotechnology community,'' said Richard J. Freer, Chairman, CBI.
biz.yahoo.com |
